PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different Glucose Tolerance under Statin Therapy
暂无分享,去创建一个
M. Järvelin | S. Keinänen-Kiukaanniemi | M. Tulppo | J. Jokelainen | J. Leppäluoto | K. Herzig | J. Auvinen | K. Mäkelä | Ville Stenbäck
[1] D. Duprez,et al. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects , 2020, Vascular health and risk management.
[2] G. Limongelli,et al. Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term inhibition , 2020, BioFactors.
[3] R. de Caterina,et al. Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina , 2019, Cardiovascular Diabetology.
[4] M. Järvelin,et al. Vitamin D Status and Components of Metabolic Syndrome in Older Subjects from Northern Finland (Latitude 65°North) , 2019, Nutrients.
[5] S. Keinänen-Kiukaanniemi,et al. Effect of Physical Activity on Plasma PCSK9 in Subjects With High Risk for Type 2 Diabetes , 2019, Front. Physiol..
[6] S. Keinänen-Kiukaanniemi,et al. Association of Physical Activity With Telomere Length Among Elderly Adults - The Oulu Cohort 1945 , 2019, Front. Physiol..
[7] A. Virdis,et al. Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors. , 2019, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[8] M. Ruscica,et al. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor , 2018, European heart journal.
[9] J. Danesh,et al. Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment , 2018, Circulation.
[10] Adipokines and inflammatory markers in elderly subjects with high risk of type 2 diabetes and cardiovascular disease , 2018, Scientific Reports.
[11] R. Laaksonen,et al. PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions. , 2018, Atherosclerosis.
[12] P. Barter,et al. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. , 2017, Journal of clinical lipidology.
[13] A. Sposito,et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years , 2017, Diabetes Care.
[14] M. Banach,et al. PCSK9 and diabetes: is there a link? , 2017, Drug discovery today.
[15] A. Lichtenstein,et al. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans , 2017, Circulation.
[16] S. Keinänen-Kiukaanniemi,et al. Measuring Physical Activity in Free-Living Conditions—Comparison of Three Accelerometry-Based Methods , 2017, Front. Physiol..
[17] Jennifer G. Robinson,et al. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies , 2016, European heart journal.
[18] R. Ferré,et al. Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders. , 2016, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.
[19] L. Räber,et al. Prognostic value of PCSK9 levels in patients with acute coronary syndromes. , 2016, European heart journal.
[20] M. Sakly,et al. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients. , 2015, Journal of diabetes and its complications.
[21] Nidhi Bansal,et al. Prediabetes diagnosis and treatment: A review. , 2015, World journal of diabetes.
[22] Cheng-gang Zhu,et al. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. , 2014, Journal of clinical lipidology.
[23] A. Kwakernaak,et al. Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins. , 2014, Clinical biochemistry.
[24] D. Accili,et al. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. , 2012, The Journal of clinical investigation.
[25] F. Cipollone,et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. , 2012, Atherosclerosis.
[26] S. Klein,et al. Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people. , 2011, Translational research : the journal of laboratory and clinical medicine.
[27] M. Krempf,et al. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes. , 2011, Atherosclerosis.
[28] Yasuo Ohashi,et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.
[29] Annik Prat,et al. PCSK9‐deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities , 2010, FEBS letters.
[30] Reino Laatikainen,et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. , 2009, The Analyst.
[31] Jonathan C. Cohen,et al. Genetic and metabolic determinants of plasma PCSK9 levels. , 2009, The Journal of clinical endocrinology and metabolism.
[32] J. Mayne,et al. Lipids in Health and Disease BioMed Central , 2008 .
[33] W. Alborn,et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 Published, JLR Papers in Press, November 21, 2007. , 2008, Journal of Lipid Research.
[34] Anna Castiglione,et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population , 2006, BMC gastroenterology.
[35] J. Ekoé,et al. Diagnosis and Classification of Diabetes Mellitus , 2019, Encyclopedia of Endocrine Diseases.
[36] Alexander Pertsemlidis,et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 , 2005, Nature Genetics.
[37] L. Bernier,et al. Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[38] Ronald M Peshock,et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. , 2004, The American journal of cardiology.
[39] J. Weissenbach,et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.